285983-48-4 | 3-[3-tert-butyl-1-(4-methylphenyl)-1H-pyrazol-5-yl]-1-{4-[2-(morpholin-4-yl)ethoxy]naphthalen-1-yl}urea

Packsize	Purity	Availability	Price	Discounted Price
1mg	98%	in stock	$19.00	$14.00
2mg	98%	in stock	$23.00	$17.00
5mg	98%	in stock	$31.00	$22.00
10mg	98%	in stock	$42.00	$30.00
50mg	98%	in stock	$92.00	$65.00
100mg	98%	in stock	$111.00	$78.00
250mg	98%	in stock	$159.00	$111.00
1g	98%	in stock	$396.00	$277.00
5g	98%	in stock	$1,879.00	$1,316.00

Description

• Catalog Number: AB34343
• Chemical Name: 3-[3-tert-butyl-1-(4-methylphenyl)-1H-pyrazol-5-yl]-1-{4-[2-(morpholin-4-yl)ethoxy]naphthalen-1-yl}urea
• CAS Number: 285983-48-4
• Molecular Formula: C31H37N5O3
• Molecular Weight: 527.6572
• MDL Number: MFCD09752957
• SMILES: O=C(Nc1cc(nn1c1ccc(cc1)C)C(C)(C)C)Nc1ccc(c2c1cccc2)OCCN1CCOCC1

Computed Properties

• Complexity: 777
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 39
• Hydrogen Bond Acceptor Count: 5
• Hydrogen Bond Donor Count: 2
• Rotatable Bond Count: 8
• XLogP3: 5.7

Literature

• Small molecule discoidin domain receptor kinase inhibitors and potential medical applications.

  Journal of medicinal chemistry 20150423

• Defining a role for acid sphingomyelinase in the p38/interleukin-6 pathway.

  The Journal of biological chemistry 20140808

• Gene expression profiles in engineered cardiac tissues respond to mechanical loading and inhibition of tyrosine kinases.

  Physiological reports 20131001

• Identification of potent Yes1 kinase inhibitors using a library screening approach.

  Bioorganic & medicinal chemistry letters 20130801

• Identification, synthesis, and biological evaluation of 6-[(6R)-2-(4-fluorophenyl)-6-(hydroxymethyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidin-3-yl]-2-(2-methylphenyl)pyridazin-3(2H)-one (AS1940477), a potent p38 MAP kinase inhibitor.

  Journal of medicinal chemistry 20120913

• Mitogen-activated protein kinase-activated protein kinase 2 (MAPKAP-K2) as an antiinflammatory target: discovery and in vivo activity of selective pyrazolo[1,5-a]pyrimidine inhibitors using a focused library and structure-based optimization approach.

  Journal of medicinal chemistry 20120809

• Design and synthesis of novel p38α MAP kinase inhibitors: discovery of pyrazole-benzyl ureas bearing 2-molpholinopyrimidine moiety.

  Bioorganic & medicinal chemistry letters 20120801

• p38 MAPK inhibition suppresses the TLR-hypersensitive phenotype in FANCC- and FANCA-deficient mononuclear phagocytes.

  Blood 20120301

• Rational approaches to improving selectivity in drug design.

  Journal of medicinal chemistry 20120223

• Structure-based design, synthesis and biological evaluation of N-pyrazole, N'-thiazole urea inhibitors of MAP kinase p38α.

  European journal of medicinal chemistry 20120201

• Discovery of novel orally active anti-inflammatory N-phenylpyrazolyl-N-glycinyl-hydrazone derivatives that inhibit TNF-α production.

  PloS one 20120101

• Molecular dynamics simulation and free energy calculation studies of the binding mechanism of allosteric inhibitors with p38α MAP kinase.

  Journal of chemical information and modeling 20111227

• Skepinone-L is a selective p38 mitogen-activated protein kinase inhibitor.

  Nature chemical biology 20111225

• Discovery of a novel class of non-ATP site DFG-out state p38 inhibitors utilizing computationally assisted virtual fragment-based drug design (vFBDD).

  Bioorganic & medicinal chemistry letters 20111201

• Design and synthesis of inhaled p38 inhibitors for the treatment of chronic obstructive pulmonary disease.

  Journal of medicinal chemistry 20111124

• 1,7-Naphthyridine 1-oxides as novel potent and selective inhibitors of p38 mitogen activated protein kinase.

  Journal of medicinal chemistry 20111124

• Indolin-2-one p38α inhibitors III: bioisosteric amide replacement.

  Bioorganic & medicinal chemistry letters 20111101

• Comprehensive analysis of kinase inhibitor selectivity.

  Nature biotechnology 20111030

• A possible mechanism for hepatotoxicity induced by BIRB-796, an orally active p38 mitogen-activated protein kinase inhibitor.

  Journal of applied toxicology : JAT 20111001

• Design, synthesis, and biological activity of urea derivatives as anaplastic lymphoma kinase inhibitors.

  ChemMedChem 20110905

• Synergistic effects of p38 mitogen-activated protein kinase inhibition with a corticosteroid in alveolar macrophages from patients with chronic obstructive pulmonary disease.

  The Journal of pharmacology and experimental therapeutics 20110901

• Discovery, synthesis, and investigation of the antitumor activity of novel piperazinylpyrimidine derivatives.

  European journal of medicinal chemistry 20110601

• Activation state-dependent binding of small molecule kinase inhibitors: structural insights from biochemistry.

  Chemistry & biology 20101124

• Biochemical and biophysical characterization of unique switch pocket inhibitors of p38α.

  Bioorganic & medicinal chemistry letters 20101001

• X-ray crystal structure of JNK2 complexed with the p38alpha inhibitor BIRB796: insights into the rational design of DFG-out binding MAP kinase inhibitors.

  Bioorganic & medicinal chemistry letters 20100901

• The design, synthesis, and evaluation of 8 hybrid DFG-out allosteric kinase inhibitors: a structural analysis of the binding interactions of Gleevec, Nexavar, and BIRB-796.

  Bioorganic & medicinal chemistry 20100801

• Analysis of imatinib and sorafenib binding to p38alpha compared with c-Abl and b-Raf provides structural insights for understanding the selectivity of inhibitors targeting the DFG-out form of protein kinases.

  Biochemistry 20100504

• Mitogen-activated protein kinase phosphatase-1 negatively regulates the expression of interleukin-6, interleukin-8, and cyclooxygenase-2 in A549 human lung epithelial cells.

  The Journal of pharmacology and experimental therapeutics 20100401

• Displacement assay for the detection of stabilizers of inactive kinase conformations.

  Journal of medicinal chemistry 20100114

• Role of protein haptenation in triggering maturation events in the dendritic cell surrogate cell line THP-1.

  Toxicology and applied pharmacology 20090715

• A new screening assay for allosteric inhibitors of cSrc.

  Nature chemical biology 20090601

• Structural characterization of proline-rich tyrosine kinase 2 (PYK2) reveals a unique (DFG-out) conformation and enables inhibitor design.

  The Journal of biological chemistry 20090508

• Discovery and characterization of the N-phenyl-N'-naphthylurea class of p38 kinase inhibitors.

  Bioorganic & medicinal chemistry letters 20090501

• Phosphorylation of Ewing's sarcoma protein (EWS) and EWS-Fli1 in response to DNA damage.

  The Biochemical journal 20090315

• Inhibition of p38: has the fat lady sung?

  Arthritis and rheumatism 20090201

• Biphenyl amide p38 kinase inhibitors 4: DFG-in and DFG-out binding modes.

  Bioorganic & medicinal chemistry letters 20080801

• Design, synthesis, and biological evaluation of novel Tri- and tetrasubstituted imidazoles as highly potent and specific ATP-mimetic inhibitors of p38 MAP kinase: focus on optimized interactions with the enzyme's surface-exposed front region.

  Journal of medicinal chemistry 20080724

• Microwave-assisted synthesis of 5-aminopyrazol-4-yl ketones and the p38(MAPK) inhibitor RO3201195 for study in Werner syndrome cells.

  Bioorganic & medicinal chemistry letters 20080701

• Structure-based design and subsequent optimization of 2-tolyl-(1,2,3-triazol-1-yl-4-carboxamide) inhibitors of p38 MAP kinase.

  Bioorganic & medicinal chemistry letters 20080601

• The design and synthesis of novel alpha-ketoamide-based p38 MAP kinase inhibitors.

  Bioorganic & medicinal chemistry letters 20080315

• A quantitative analysis of kinase inhibitor selectivity.

  Nature biotechnology 20080101

• The selectivity of protein kinase inhibitors: a further update.

  The Biochemical journal 20071215

• New modifications to the area of pyrazole-naphthyl urea based p38 MAP kinase inhibitors that bind to the adenine/ATP site.

  Bioorganic & medicinal chemistry letters 20070801

• Targeted therapy and the T315I mutation in Philadelphia-positive leukemias.

  Haematologica 20070401

• p38 mitogen-activated protein kinase inhibition ameliorates angiotensin II-induced target organ damage.

  Hypertension (Dallas, Tex. : 1979) 20070301

• BIRB 796 enhances cytotoxicity triggered by bortezomib, heat shock protein (Hsp) 90 inhibitor, and dexamethasone via inhibition of p38 mitogen-activated protein kinase/Hsp27 pathway in multiple myeloma cell lines and inhibits paracrine tumour growth.

  British journal of haematology 20070201

• The role of IFN-gamma in regulation of IFN-gamma-inducible protein 10 (IP-10) expression in lung epithelial cell and peripheral blood mononuclear cell co-cultures.

  Respiratory research 20070101

• Design, synthesis, and biological evaluation of phenylamino-substituted 6,11-dihydro-dibenzo[b,e]oxepin-11-ones and dibenzo[a,d]cycloheptan-5-ones: novel p38 MAP kinase inhibitors.

  Journal of medicinal chemistry 20061228

• Discovery and design of benzimidazolone based inhibitors of p38 MAP kinase.

  Bioorganic & medicinal chemistry letters 20061215

• Microwave-assisted synthesis of N-pyrazole ureas and the p38alpha inhibitor BIRB 796 for study into accelerated cell ageing.

  Organic & biomolecular chemistry 20061121

• Homogeneous time-resolved fluorescence and its applications for kinase assays in drug discovery.

  Analytical biochemistry 20060915

• Enzyme fragment complementation binding assay for p38alpha mitogen-activated protein kinase to study the binding kinetics of enzyme inhibitors.

  Assay and drug development technologies 20060801

• Rational design of inhibitors that bind to inactive kinase conformations.

  Nature chemical biology 20060701

• BIRB-796 is not an effective ABL(T315I) inhibitor.

  Nature biotechnology 20051001

• Features of selective kinase inhibitors.

  Chemistry & biology 20050601

• BIRB796 inhibits all p38 MAPK isoforms in vitro and in vivo.

  The Journal of biological chemistry 20050520

• HierS: hierarchical scaffold clustering using topological chemical graphs.

  Journal of medicinal chemistry 20050505

• A small molecule-kinase interaction map for clinical kinase inhibitors.

  Nature biotechnology 20050301

• P38 mitogen activated protein kinase is involved in the downregulation of granulocyte CXC chemokine receptors 1 and 2 during human endotoxemia.

  Journal of clinical immunology 20040101

• Thermal denaturation: a method to rank slow binding, high-affinity P38alpha MAP kinase inhibitors.

  Journal of medicinal chemistry 20031023

• Structure-activity relationships of the p38alpha MAP kinase inhibitor 1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)naph- thalen-1-yl]urea (BIRB 796).

  Journal of medicinal chemistry 20031023

• The kinetics of binding to p38MAP kinase by analogues of BIRB 796.

  Bioorganic & medicinal chemistry letters 20030915

• Anti-arthritic agents--SMi conference: trapping cytokines. 28-29 April 2003, London, UK.

  IDrugs : the investigational drugs journal 20030601

• Pyrazole urea-based inhibitors of p38 MAP kinase: from lead compound to clinical candidate.

  Journal of medicinal chemistry 20020704

• Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site.

  Nature structural biology 20020401